News

At the 96th Annual Meeting of Japanese Gastric Cancer Association, an interim report on the Phase Ⅰ/Ⅱ trial of intraperitoneal infusion of GAIA-102 for gastric/pancreatic cancer will be presented.

At the 9th Annual Innate Killer Summit (IKS2024), Clinical Activity of GAIA-102 Against Refractory/Relapsed Pediatric Solid Tumors will be presented.

At the 38th Annual Meeting of Society of Immunotherapy of Cancer (SITC2023), Interim Report of Phase I Clinical Trial of Pseudoprogression and subsequent shrinkage of refractory/relapsed pediatric solid tumors induced by GAIA-102

At the 38th Society for Immunotherapy of Cancer (SITC 2023), an interim report on the Phase I trial of GAIA-102 for pediatric solid malignant tumors will be presented.

At the Asian Oncology Society 2023 (AOS 2023), an interim report on the Phase I/II trial of GAIA-102 for patients with microsatellite stable (MSS) advanced gastric/pancreatic cancer with malignant ascites was presented.

At the 65th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology, an interim report on the Phase I trial of GAIA-102 for pediatric solid malignant tumors will be presented.

Cellab Healthcare Service (Cellab HS) and GAIA BioMedicine (GAIA) jointly held a press conference to announce that the two firms had executed a business agreement concerning the production of GAIA-102.

GAIA BIOMEDICINE & TREEFROG THERAPEUTICS ANNOUNCE COLLABORATION FOR THE EXPANSION OF ALLOGENEIC NK-LIKE CELLS AGAINST SOLID TUMORS

Kyushu University Hospital had received IND clearance from the PMDA for a Phase Ⅰ investigator-initiated clinical trial of GAIA-102 for pediatric cancer patients with recurrent and refractory neuroblastoma (“NB”) or solid pediatric malignancies with pulmonary metastases

Kyushu University Hospital had received IND clearance from the PMDA for a Phase Ⅰ/Ⅱ investigator-initiated clinical trial of GAIA-102 for patients with Advanced Gastrointestinal Cancer of Microsatellite Stable (“MSS”) with Malignant Ascites